{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hirsutism/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"84d0d634-74f6-5808-8f94-da5030ec05c6","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 0ba80388-b850-41b4-838c-29d82a6176bc --><h2>Changes</h2><!-- end field 0ba80388-b850-41b4-838c-29d82a6176bc -->","summary":null,"htmlStringContent":"<!-- begin item 0c41a4e7-741c-4a05-b11b-c34d05383e21 --><!-- begin field b18056c4-5bb0-4cff-9bfd-f80ba559107f --><p><strong>July 2020</strong> — minor update. New advice on cyproterone acetate added to the management of hirsutism in premenopausal women section.</p><p><strong>October 2019 to February 2020</strong> — reviewed. Literature searches were conducted in September 2019 and updated in January 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic.</p><p>Discussion of the use of a scoring system for diagnosis has been added. The section on assessing for underlying causes has been expanded and minor changes made to the recommendations on further investigations. Changes have been made to to the referral section. In the management section, recommendations on choice of combined oral contraceptive to treat hirsutism in a premenopausal woman have undergone an update and links to patient information are included. The structure of the prescribing information section has been altered.</p><!-- end field b18056c4-5bb0-4cff-9bfd-f80ba559107f --><!-- end item 0c41a4e7-741c-4a05-b11b-c34d05383e21 -->","topic":{"id":"f7bb546f-c63b-5f36-8592-742d53a300ba","topicId":"6cd0021b-eeb7-4f76-9627-4f095658d33a","topicName":"Hirsutism","slug":"hirsutism","lastRevised":"Last revised in July 2020","chapters":[{"id":"7f1b7b92-6387-5893-b9c1-1b0fe5e6921f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ad41ddff-180c-5c56-9fa8-cfcaa4b301ac","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4e6e27c3-ace8-5785-bc5d-74954333ce03","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84d0d634-74f6-5808-8f94-da5030ec05c6","slug":"changes","fullItemName":"Changes"},{"id":"24cd5147-9eea-5049-abb9-bbff6b2e15e8","slug":"update","fullItemName":"Update"}]},{"id":"bccddc08-eaf5-58bc-b91c-222a0631380a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d59efd74-c7e8-5a58-88a9-274b74de9cc7","slug":"goals","fullItemName":"Goals"},{"id":"3e4b60ae-49dd-58fa-8977-9a8f93804089","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fb5d6918-d9cd-57de-8ef8-09ac15afb519","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fb74a918-ba53-56c2-b640-6a8b38dd4d52","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0a97044d-161a-536d-99bd-e30a0b9553dd","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ed166746-cb44-593f-aa91-2daa54e9df51","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"530429b5-0393-529c-874a-7270e7bccb64","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2c5b6cec-8e35-5953-a425-773d40af6f62","slug":"definition","fullItemName":"Definition"},{"id":"7c04b952-69e3-54ba-abf5-964402df757c","slug":"causes","fullItemName":"Causes"},{"id":"1ab4046f-c4e7-520f-893f-e09d2db4390d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"dce06012-6849-5ef4-ab2b-0c84dc64de89","slug":"complications","fullItemName":"Complications"}]},{"id":"0e4a9c3d-b4db-57a6-b036-9e01073ecafc","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a58667b3-2a20-5be2-81aa-4b35ba1bc423","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"fc818766-2cdb-52a0-ad0e-7925d2deab29","slug":"assessment-for-an-underlying-cause","fullItemName":"Assessment for an underlying cause"},{"id":"3e40d667-a42d-56c7-a222-6eb858be7c6d","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"684a1492-2308-5cae-b75d-1460cf238959","fullItemName":"Management","slug":"management","subChapters":[{"id":"eb3e5264-aa93-5618-a326-1f9052e41577","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"61f39625-be0c-52a3-bdb4-7f1b9eaf0ffd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4573c138-4cd9-557f-9ff3-297c6187958a","slug":"topical-eflornithine","fullItemName":"Topical eflornithine"}]},{"id":"1d2fa7d5-926c-5ced-b5ff-0c103d1ddbbc","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3154c9fd-0eb5-5ee3-8a69-a18ed1a66193","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"243b8cac-0f37-5266-bf46-8279e00461db","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5fab04c2-7dc7-5ebd-89cd-f693a3cd663f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b5b1cd8e-118a-5aab-bc89-4fa265c0b038","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d0d01f8a-60fc-5ef2-94a6-9d894ebe74d4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"74f5177a-4053-5623-b286-63a07a583386","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"34dca8b6-44ff-5ef5-8816-48aa07f93aff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4e6e27c3-ace8-5785-bc5d-74954333ce03","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"7591db60-b0b9-5f89-9c3a-c963036a1585","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field ccae0ab7-4d72-4dfe-a871-3a783e209db6 --><h3>Previous changes</h3><!-- end field ccae0ab7-4d72-4dfe-a871-3a783e209db6 -->","summary":null,"htmlStringContent":"<!-- begin item 3459ea00-fcc3-47dc-a13c-0d9ef5e1413b --><!-- begin field 0355ebe5-4a67-47cf-9fec-6124d6b13e1e --><p><strong>December 2014</strong> — reviewed. A literature search was conducted in September 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. No major changes to recommendations have been made. However, the Medicines and Healthcare products Regulatory Agency (MHRA) warning that the venous thromboembolism risk with Dianette<sup>® </sup>is likely to be similar to that with Yasmin<sup>® </sup>has been included in the topic. A prescribing information section for eflornithine cream has also been added.</p><p><strong>May 2013</strong> — minor update. Eflornithine cream is now only licensed for women over 18 years of age. The text and the prescriptions have been amended to reflect this.</p><p><strong>June 2011</strong> — minor update. Broken link fixed. Issued June 2011.</p><p><strong>September 2009 to January 2010</strong> — this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 0355ebe5-4a67-47cf-9fec-6124d6b13e1e --><!-- end item 3459ea00-fcc3-47dc-a13c-0d9ef5e1413b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}